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Background: Long-term persistence to treatment for chronic disease is difficult for patients to achieve, regardless
of the disease or medication being used. The objective of this investigation was to examine treatment persistence
with glatiramer acetate (GA) relative to available disease-modifying therapies (DMT) for multiple sclerosis (MS) over
12-, 24- and 36-month periods.
Methods: Data from Clinformatics™ for DataMart affiliated with OptumInsight was used to identify patients using
DMT between 2001 and 2010. Patients with 12, 24, and 36 months of follow-up were included. Persistence was
defined as continuous use of the same DMT for the duration of follow-up regardless of treatment gaps. Regimen
changes including re-initiation of therapy following gaps of 15 days or more, switching therapy, and DMT
discontinuation were investigated. Descriptive statistics were used to summarize the results.
Results: Cohorts of GA users with 12 months (n = 12,144), 24 months (n = 7,386) and 36 months (n = 4,693) of
follow-up were identified. Persistence rates with GA were 80% for all time periods; discontinuation rates declined
over time while switching increased modestly. In contrast, the full DMT-treated cohorts showed persistent rates of
68.3% at 12 months (n = 35,312), 53.9% at 24 months (n = 21,927), and 70.1% at 36 months (n = 14,343). As with
these full DMT-treated cohorts, the proportion of GA users remaining on their initial therapy without a gap of 15
days or more decreased with length of follow-up. However, the proportion of GA users with a gap in treatment
who re-initiated GA increased over time (64.4% at 12 months; 75.1% at 24 months, and 80.1% at 36 months) while
those in the full DMT-treated cohorts re-initiated therapy at rates of only 50-60%.
Conclusions: Persistence rates for GA were 80% for the 12-, 24- and 36-month time periods in contrast with the full
DMT-treated cohorts whose persistence rates never exceeded 70.0%. Although there were more gaps in therapy of
15 days or more with all DMT over time, the proportion of GA users re-initiating therapy increased with follow-up
contributing to the steady persistence. Therapy persistence is essential to achieve the desired outcomes in MS.
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Multiple sclerosis (MS) is a neurological condition char-
acterized by axonal loss and acute focal inflammatory
demyelination [1]. The incidence of MS in the white
population of the United States (US) in 2000 was estimated
at 7.3 cases per 100,000 individuals, and the prevalence
rate was 191 cases per 100,000 individuals [2]. The disease
affects approximately 400,000 in the US and 2.3 million
people globally [3]. Diagnosis typically occurs between
20 and 50 years of age [3]. MS occurs more frequently
in women than men and in Caucasians more often than
in other ethnic groups [4]. Approximately 85% of the
cases of MS are initially diagnosed as relapsing-remitting
multiple sclerosis (RRMS), which is characterized by
disease exacerbations (new or recurring symptoms) and
periods of remission [5].
Disease-modifying therapies (DMT) in conjunction with
usual symptomatic and supportive care are the primary
treatments for MS. Currently available DMTs include
glatiramer acetate (GA; Copaxone, Teva Pharmaceuticals
USA, Inc., North Wales, PA), intramuscular interferon
beta-1a (IFNβ-1a IM; Avonex, Biogen Idec, Cambridge,
MA), subcutaneous interferon beta-1a (IFNβ-1a SC; Rebif,
EMD Serono Inc., Rockland, MA), interferon beta-1b
(IFNβ-1b; Betaseron, Bayer Healthcare Pharmaceuticals,
Inc., Montville, NJ; Extavia; Novartis Pharmaceutical
Corporation, East Hanover, NJ), natalizumab (NZ; Tysabri,
Biogen Idec, Cambridge, MA), fingolimod (FG; Gilenya,
Novartis Pharmaceutical Corporation, East Hanover,
NJ), teriflunomide (TF; Aubagio, Genzyme Corpora-
tion, Cambridge, MA) and dimethyl fumarate (DF; Tecfi-
dera, Biogen Idec, Cambridge, MA). Although they are not
curative, DMTs have been shown to reduce the occurrence
of relapses and slow progression of disability [6-13].
Similar to patients with other chronic diseases, MS
patients often have gaps in treatment, sometimes switch
therapies, or discontinue treatment altogether. In a chart
review of MS patients, treatment interruptions were
most frequent in the first 6 months after initiation, with
perceived lack of efficacy the most common reason for
interruption [14]. In other studies, key factors identified
as influencing discontinuation and persistence failure
in MS patients have included adverse events, fatigue
associated with MS treatment, lack of efficacy, injection
anxiety/problems, and patient out-of-pocket cost [15-22].
A study of patients at a large, multispecialty physician
practice in the US also showed the early decline in
DMT persistence. Of 25 patients initiating a DMT in
the two-year study period, 26% were non-persistent to
therapy within 4 months, 36% within 8 months and
42% within 14 months after initiation [23].
Although the published literature includes several studies
dealing with persistence to DMT, most have involved
small samples of patients with MS and did not followthem to look for persistence trends over three years
or more. The objective of this study is to investigate
treatment persistence with GA relative to available DMT




The administrative patient claims data used in this
study included pharmacy claims, and patient eligibility
information along with medical claims from United
Health Group (UHG) and non-UHG plans. The indi-
viduals covered by these health plans, about 32 million
annual lives in 2010, are geographically diverse across
the US, with greatest representation in the South and
Midwest US census regions. The plans provide fully
insured coverage for outpatient prescription medication,
professional (e.g., physician), and facility (e.g., hospital)
services. Outpatient pharmacy claims provide, among other
information, National Drug Codes (NDC) for dispensed
medications, quantity dispensed, drug strength, days supply,
provider specialty code, and health plan and patient costs.
No identifiable protected health information was extracted
or accessed during the course of the study. Pursuant to
the Health Insurance Portability and Accountability Act,
the use of de-identified data does not require Institutional
Review Board approval or waiver of authorization [24].
Patient identification
Patients were selected for this analysis if they had evidence
of MS as shown by an International Classification of
Diseases, Ninth Revision (ICD-9) diagnostic code 340
and a claim for a marketed MS therapy between January
2001 and December 2008. Patients were required to have
at least one claim for a marketed DMT during this time
period as well as at least 24 months of insurance eligibility
from the first treatment identified during the analysis
period; this extended the analysis window to December
2010. MS therapies included in this analysis were GA,
IFNβ-1a IM, IFNβ-1a SC, IFNβ-1b, and NZ. The oral
therapies, FG, TF and DF, were not included as they either
entered the market near the end of this analysis period
(FG) and users did not meet the inclusion criteria, or
they have come to the market since 2010 (TF and DF).
Subject cohorts
Three patient cohorts were examined based on follow-up
information: patients with a minimum of 12 months of
follow-up from the time of initiating a DMT, patients with
a minimum of 24 months of follow-up, and patients with
a minimum of 36 months of follow-up. These cohorts
were not mutually exclusive; i.e., patients in the 36-month
group could also be included in the 12 and 24-month
groups. Persistence was defined as continuous use of the
Table 1 Patient demographic characteristics*
12 months 24 months 36 months
Overall GA Overall GA Overall GA
N 35,312 12,144 21,927 7,386 14,315 4,693
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treatment gaps. Analyses of persistence and regimen
changes were developed for patients initiating GA therapy
and the cohort of those initiating any available DMT in
the time frame.Age
≤18 0.6% 0.7% 0.7% 0.7% 0.8% 0.8%
19-35 22.4% 21.7% 21.1% 20.5% 19.2% 18.8%
36-50 50.2% 50.3% 51.5% 51.7% 52.3% 52.4%
51-62 24.2% 24.5% 24.5% 24.6% 25.6% 25.7%
≥63 2.6% 2.8% 2.3% 2.5% 2.2% 2.2%
Gender
Female 76.5% 78.2% 76.7% 78.6% 76.6% 78.6%
*Cohorts are subsets of one another.Regimen changes
A patient was defined as having a gap in therapy if a
prescription was not filled for the initial DMT before the
days supply of its previous prescription plus a 15-day grace
period expired. Fifteen days was used in this definition
based on an analysis of the entire ten years of claims
data that revealed that this was the most common
threshold for a therapy gap. A patient was defined as
having re-initiated therapy if s/he had a gap in initial DMT
of at least 15 days and then filled another prescription
for the same therapy at some point after the gap. A
switch in therapy was defined as a prescription fill for
a marketed MS therapy other than the initial DMT in
a case where the patient stopped filling prescriptions
for the initial MS therapy. Combination therapy was
defined as a prescription fill for a marketed MS therapy
other than the initial DMT prior to a gap occurring in
the initial DMT; it also required a subsequent prescrip-
tion fill for the initial DMT to confirm continued use.
Patients were double counted if they had more than
one regimen change in the analysis period. As a result,
the total percentages presented below may be greater
than 100%.Results
Sample characteristics
There were 35,312 MS patients with 12 months of follow-
up including 12,144 (34.4%) patients on GA therapy;
21,927 patients were identified with 24 months of follow-
up, including 7,386 (33.7%) on GA therapy and 14,343
patients with 36 months of follow-up, including 4,693
(32.7%) who were using GA. The declining size of the
samples with each extension of follow-up is due to
changes in insurance coverage that make patients ineli-
gible for inclusion in the claims database.
Age and gender were available for all three patient
groups. Patient characteristics for the overall cohorts
and GA initiator cohorts are presented in Table 1. The
overall sample and GA initiating patients were similar
with respect to age and gender. The 12-, 24- and 36-
month cohorts also had similar demographic character-
istics. Approximately 50% of patients were between 36
and 50 years of age at the time of the first identified
MS treatment in the study period. About three-quarters
(76%) of the overall sample were female. The percentage
of females in the GA initiator cohort was slightly higher
at 78%.12 Months following DMT initiation
Of patients initiating GA, 42.6% (5,178) remained on GA
for the entire 12 months without a gap in therapy of
15 days or more; 2.1% (254) switched from GA to
another MS therapy; 1.9% (233) appeared to use GA as
combination therapy, and 52.4% (6,369) had a gap in
therapy of ≥15 days. Of the GA patients with a gap in
therapy, 64.4% (4,101) re-initiated GA, 4.3% (273) switched
to another therapy, and 30.8% (1,960) discontinued all
DMT. Among patients with a minimum of 12 months
of follow-up, the persistence rate with GA was 79.5%.
When there was a regimen change, the average time
to the first change in treatment was 124 days. The 12-
month persistence experiences for those initiating GA
are presented in Figure 1.
For the full DMT-treated cohort, 47.2% (16,665) of the
overall cohort remained on their initial treatment for
the entire year without a gap; 10.0% (3,454) switched to
a different MS therapy. A gap in therapy of 15 days or
more was observed for 17,222 (48.8%) of the overall
cohort. Of the patients with a gap in therapy, 61.4%
(10,573) re-initiated their initial therapy and 44.9%
(7,727) discontinued all disease-modifying therapy (DMT).
The persistence rate for the entire DMT cohort over
12 months was 68.3%. Of those using DMT for 12 months,
more than ninety-five percent of patients were on
monotherapy for their MS, while 4.6% of patients
appeared to receive combination therapy at some point
during the analysis period. For those with a change in
therapy regimen, the average time to the first change
in treatment was 127 days.
24 Months following DMT initiation
The persistence experience of GA patients over 24 months
is outlined in Figure 2. Of the 7,386 patients initiating
GA, 24.6% remained on GA for the 24 months without
a gap in therapy of 15 days or more; 2.6% switched from
GA to another therapy, and 3.3% of patients appeared to
Figure 1 GA persistence experience at 12 months.
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patients had a gap in therapy of 15 days or more. Of the
patients whose first change of regimen was a gap, 75.1%
reinitiated GA, 0.6% appeared to add another MS therapy
(combination therapy); 5.2% switched to another therapy,
and 19.1% discontinued DMT. Accounting for those who
switched therapies or stopped using GA, the persistenceFigure 2 GA persistence experience at 24 months.rate with GA for those with a minimum of 24 months of
follow-up was 80.5%.
For the 24-month cohort of GA users who experienced
changes in their regimen, the average time to the first
change in MS treatment was 222 days. The average time
to the addition of a second therapy was 204 days, a first
gap of 15 days or more occurred an average of 218 days
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occurred, on average, 227 days after beginning GA. After
the initial therapy gap of 15 days or more, patients
reinitiating GA did so at 54 days on average, with a
treatment switch occurring an average of 109 days after
the initial treatment gap.
In contrast, 30% (6,484) of the overall DMT-treated
cohort remained on their initial therapy for the entire
24 months without a gap of 15 days or more; 16.0% (3,448)
of patients switched to another MS therapy; and 67%
(14,650) had a gap in therapy ≥15 days. Of the patients
with a gap in therapy, 51.5% (11,172) re-initiated their
initial MS therapy; 7.6% appeared to be on combination
therapy at some point during the 24-month period; and
30% (6,658) discontinued all DMT. The persistence rate
with any DMT over the 24 months was 53.9%. When
there was a regimen change, the average time to the
first change in therapy was 215 days.
36 Months following DMT initiation
Figure 3 describes the persistence experience of GA
patients at 36 months after initiation. Of those patients
using GA, 16.8% (787) stayed on GA for the entire
36-month period without a gap in therapy of 15 days
or more. 4.1% (194) switched from GA to another MS
therapy and 2.4% (111) appeared to be using GA as
combination therapy. Of patients with a gap in therapy of
15 days or more (3,601; 76.7%), 80.1% (2,884) reinitiated
GA therapy; 5.1% (183) switched to another therapy and
14.0% (503) discontinued all therapies. Accounting for
those who switched from GA to another therapy orFigure 3 GA persistence experience at 36 months.discontinued GA and all DMT, the persistence rate
with GA after 36 months of followed was 81.2%. When
a regimen change was made, the average time to the
first change in treatment was 296 days.
For the full DMT-treated cohort at 36 months after
initiation of a DMT, 21.0% (2,961) of patients remained
on their initial therapy; 20% (2,870) had switched therapies
and 76.0% (10,912) had a gap in therapy ≥15 days. Of the
patients with a gap in therapy, 56.0% (7,936) reinitiated
their initial therapy. Combination therapy was observed in
9.9% of patients at some point in the analysis period and
14% (1,416) discontinued all DMT yielding a persistence
rate with all available DMT of 70.1%. When a regimen
change was made, the average time to the first change
in treatment was 309 days.
Discussion
Persistence for this investigation was defined as continuous
use of the same DMT for the duration of follow-up (i.e.,
12 months, 24 months, 36 months) regardless of treatment
gaps. Among patients with a minimum of 12 months of
follow-up, the persistence rate with GA was 79.5% while
for the full cohort of DMT-treated patients the persistence
rate at 12 months was 68.3%. This can be compared to the
persistence investigation conducted by Reynolds et al.
using a different US administrative claims database with
MS patient-level data from 1996 to 2005 [25]. They found
the persistence rate at 12 months for GA was 68.5%,
and for all DMTs included in their study it was 65.1%.
Differences in persistence rates between the studies may
be the result of the time windows used for data extraction,
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study. This study with a data extraction window of 2001
to 2010 included NZ that was not available for the
Reynolds study. This could have resulted in more therapy
switching and the corresponding washout periods without
DMT that would decrease the persistence rates for all
DMT. The data extraction time window used by Reynolds
et al. (1996–2005) corresponds to the entry to the market
of GA, and IFNβ-1a IM in 1996 and IFNβ-1a SC in
2002. Patients beginning new therapies were in the
most vulnerable period for interruptions in therapy and
that may be reflected in lower persistence rates than those
seen in the later time window of this study. Reynolds et al.
included 6,134 MS patients in their investigation, while
this study had 35,312 MS patients available for the 12-
month cohort. The characteristics of the patient samples
in terms of age, gender and geographic distribution were
very similar.
When patients with a minimum of two years of follow-
up were examined for this study, the persistence rate
for GA increased slightly to 80.5% and the corresponding
rate for the full DMT-treated cohort fell to 53.9%. With
36 months of follow-up, the persistence rate for GA
increased modestly to 81.2% and the persistence rate for
the full DMT-treated cohort rose to 70.1%. Relative to the
12-month cohort, the persistence rates for GA remained
stable for 24 and 36 months with modest increases in
therapy switching and decreases in discontinuation. For
the full DMT-treated cohort there was greater fluctuation
in persistence rates over the three years. The proportion
switching therapies increased with duration of follow-up
while the proportion discontinuing DMT increased from
12 months to 24 months but declined after 36 months.
This may reflect the introduction NZ in 2006 and the
fact that patients needed to stop all DMT for several
months for a washout period before they initiated NZ
therapy. Results from this investigation do show some
similarity to those of other investigators. Margolis et al.
followed a cohort of newly diagnosed MS patients for
an average of 35.7 ± 17.5 months; those who were treated
with DMT had a persistence rate of 72.3% [26]. Rio et al.
reported that 80.0% of their DMT users continued on the
same therapy without interruption after a mean follow-up
of 47 months [19], and Tremlett et al. reported that at the
end of study follow-up (mean 2.4 years), the persistence
rate for GA was 80.0% [27].
Gaps in MS therapy are commonplace and this study
shows that they increase with the duration of all DMT.
However, the proportion of GA users who re-initiated
therapy following gaps in therapy increased over time
from 64.4% at 12 months to 80.1% at 36 months. This
was in contrast to the full DMT-treated cohort that
maintained a therapy re-initiation rate of 50-60% over
36 months. The lower re-initiation rate may be attributedto some patients with more highly active disease who
were hospitalized for a relapse, treated with corticoste-
roids, or taken off their DMT to begin another therapy.
Regardless of DMT, the relatively high percentage of
patients re-initiating the same therapy after a therapy
gap may indicate that these patients are experiencing
more short-term issues such as forgetfulness, failure to
re-order medication, a problem with reimbursement or the
desire to take a drug holiday with or without a physician’s
approval.
The consequences of medication gaps have begun to
be reported and gaps have been shown to be associated
with an increased risk of MS relapse [27-29]. Tremlett
et al. reported that therapy gaps were associated with a
shorter time to first on-study relapse and trend towards
future disease progression when compared to patients
without missed doses [27].
Therapy regimen changes such as switching medication
and stopping DMT interfere with persistence. In this
study the rate of therapy switching increased over time;
4.3% of the GA cohort switched therapies in the first
12 months, 6.3% in 24 months and 8.0% over 36 months.
This trend was consistent with the full DMT-treated
cohort though the switching proportions for the GA
cohort were somewhat lower than those for the overall
sample: 10% over 12 months, 16% in 24 months and
20% over 36 months. This may reflect the results of
Reynolds et al. who reported the lowest switch rates for
GA relative to IFNβ [25]. When compared to other
published results of therapy switching in MS, Margolis
et al. reported more than twice as much DMT switching
(21.3%) at 12 months as the 9.0% reported by Reynolds
et al. [25,26]. and the 10.0% reported in this study.
However, for GA users specifically, Reynolds et al. reported
somewhat higher switch rates than those seen with this
study: 3.9% had switched to another DMT in the first 6
months, 6.4% had switched over 12 months, and 8.3%
switched over 18 months [25]. This may be related to
the earlier window of data extraction used by Reynolds
et al. corresponding to the market introduction of GA.
Unlike therapy switching that increased with duration
of therapy, the proportion discontinuing declined with
duration of therapy in this study. This is consistent with
the findings of others who have noted that the most
vulnerable time for therapy discontinuation is the first
six months of therapy [18,23]. There is evidence to suggest
that the timing of therapy discontinuation is earlier when
the reason is an adverse drug event and later when the
reason for stopping is a perceived lack of therapy effect
[18,30]. Several investigators have explored the reasons for
therapy discontinuation and they include factors related to
the disease such as the type of MS, the level of disability
or physician-documented disease progression, adverse
effects, patients’ perceptions of therapy ineffectiveness,
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and therapy cost [14-21].
Limitations
Claims database analysis allows for estimation of real-
world treatment patterns, including persistence with
individual therapies, and the strength of our analysis
derives from the large, geographically diverse population
studied. All retrospective database analyses are subject
to certain limitations, and the results of this study must
be interpreted with appropriate consideration of these
limitations. Claims data are collected primarily for payment
purposes, not research, and are subject to coding errors.
Presence of a diagnosis code for MS on a medical claim is
not positive presence of MS. The presence of a claim
for a filled prescription does not necessarily indicate
that the medication was consumed or that it was taken
as prescribed. Medications filled over-the-counter or
provided as samples by the physician were not observed
in the claims data, and regimen changes were based on
filled prescriptions. Claims-based data are constrained by
coverage limitations that determine the data available and
limit generalizability of results to managed care patients.
Limitations specific to this study include the inability to
ascertain the reasons why patients had a change in regimen.
Although claims data do not provide this information,
key factors influencing persistence and discontinuation
in MS patients in the literature include those mentioned
previously. Additionally, the study window of 2001 to
2010 did not allow an investigation of persistence with
the new generation of oral therapies for MS.
Conclusions
Persistence with GA was 80% over the 12-month, 24-
month and 36-month time periods. Although treatment
gaps of 15 days or more were common for all DMT,
higher rates of therapy re-initiation following treatment
gaps was seen with GA than with the full DMT-treated
cohort and this contributed to consistently high persist-
ence rates with GA. Persistence with the full DMT-treated
cohort fluctuated and never exceeded 70.0% over the three
time periods. Rates of switching to another MS therapy
were lower for patients initiating GA than for the full
cohort of DMT-treated patients. Therapy discontinuation
declined for all DMT over longer periods of follow-up.
Persistence with MS therapy is essential to achieve the
desired outcomes in MS. With the more recent introduction
of several oral DMTs, further investigation of long-term
therapy persistence in MS should be pursued.
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